Trial intelligence / Profile preview

Remimazolam versus propofol for anesthesia in hepatic radiofrequency ablation

ChiCTR2300078192Phase 4Not yet recruiting

Sponsor
Affiliated Hospital of North Sichuan Medical College
Start
Dec 2023
Modality
Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 4, open-label trial of remimazolam, propofol and remifentanil in hepatocellular carcinoma (HCC) (2 arms), sponsored by Affiliated Hospital of North Sichuan Medical College. Primary endpoints: Heart rate, Mean arterial blood pressure and 3 more. Planned start Dec 2023; status: not yet recruiting.

02

Drugs

remimazolampropofolremifentanil
03

Conditions

hepatocellular carcinoma (HCC)

Beyond the preview

Go deeper on ChiCTR2300078192.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on ChiCTR2300078192.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call